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ABSTRACT 
Chronic health conditions like diabetes and sleep disorders have been increasing. Previous research 
showed that diabetes and sleep disorders are interrelated. The majority of studies examining this 
relationship focused on type 2 diabetes. Although a relationship between sleep disorders and type 
1 diabetes (T1D) has been studied, investigations have been limited to youth and small samples. 
We, therefore, aimed to assess the prevalence, overall and gender-specific, and correlates, of 
obstructive sleep apnea (OSA) risk in an adult cohort with long-standing T1D.  
A total of 170 individuals with T1D attending the 25-year follow-up of the Pittsburgh 
Epidemiology of Diabetes Complications study who completed an OSA screening tool, the Berlin 
Questionnaire (BQ), were included in this cross-sectional analysis. Those scoring positively on the 
BQ and/or reported a previous OSA diagnosis were classified as being at high OSA risk.  
The OSA risk prevalence was 25.9% (25.0% among men, 26.6% among women). High 
versus low-OSA-risk individuals differed univariately with respect to markers of obesity, systolic 
blood pressure, estimated glucose disposal rate, lipid profile, and smoking history, although no 
differences were observed in hemoglobin A1c. In the final multivariable model, adjusting for sex 
and diabetes duration, body mass index (BMI) (directly, p=0.01), high-density lipoprotein (HDL) 
(inversely, p=0.03), and smoking history (directly, p=0.04) correlated with OSA risk. In gender-
specific analyses, adjusting for diabetes duration, BMI (directly, p=0.007) and HDL (inversely, 
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p=0.03) were also associated with OSA risk in women, while diastolic blood pressure (p=0.01) 
and smoking history (p=0.04) were positive OSA correlates in men. 
Our findings suggest that the prevalence of high OSA risk in adults with long-standing 
T1D is comparable to that in the general population. Given that both OSA screening tools and 
treatment are widely available, identifying high OSA risk among individuals already burdened 
with a serious chronic disease is of public health importance. Indeed, modifiable risk factors were 
independently associated with OSA risk in this study, suggesting that the adoption of a healthier 
lifestyle may reduce OSA risk in T1D, improving the wellbeing and reducing the subsequent risk 
of further complication development. Future prospective cohorts should be conducted to explore 
this hypothesis. 
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LIST OF ABBREVIATIONS
1.0  INTRODUCTION 
Along with the changing patterns of modern lifestyle that entail being more efficient but less active 
and being more aware of healthy eating but having less time to prepare healthy foods, comes the 
rise of chronic diseases. For instance, burdensome public health conditions such as diabetes and 
sleep disorders continue to rise and contribute to decreased quality of life and increased morbidity 
and mortality. In 2014, the Centers for Disease Control and Prevention estimated that 29.1 million 
Americans, or 9.3% of the population, had diabetes [1]. This figure is more than 2 times higher 
than the prevalence rate from 2000 (4.4%) and more than 3 times higher than the 1990 prevalence 
rate of 2.7% [2]. Diabetes is accompanied by other chronic disorders such as heart disease, stroke, 
hypertension, kidney disease, and blindness, among many others, and individuals who suffer from 
this chronic condition are approximately two times more likely to experience premature death in 
comparison to diabetes-free individuals of similar age [3]. Indeed, recent estimates suggest that 
diabetes is now the 7th leading cause of death in the United States [3]. Due to its widespread 
prevalence and debilitating impact, diabetes has become a national health care priority and the 
importance of addressing this serious public health condition has been well recognized. 
In 2006, the Institute of Medicine estimated that 50-70 million of the U.S. adults had 
chronic sleep and wakefulness disorders [4]. Similarly to diabetes, an increasing trend in the 
prevalence of sleep disorders has also been observed among American adults. For instance, 
according to the National Sleep Foundation’s 2001 Sleep in America Poll, the second most 
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common sleep disorder in the U.S., obstructive sleep apnea (OSA), was diagnosed among 5% of 
the randomly selected, nationally representative American adults [5]. This figure had almost 
doubled to 9% in the later conducted 2008 Sleep in America Poll [6]. Sleep apnea may be an even 
greater problem than these figures suggest, given that 75-80% of moderate or severe cases appear 
to be undiagnosed [7]. Furthermore, sleep disorders have also been linked to other health related 
conditions including hypertension, obesity, insulin resistance, cardiovascular disease, and 
impotence leading to decreased quality of life as well as to increased mortality [8].  
Interestingly, investigators have suggested that these two chronic conditions, diabetes and 
sleep disorders, are interrelated. Thus, recent large prospective studies suggested that sleep 
disorders may contribute to the risk of developing diabetes [9-12]. Conversely, it has also been 
suggested that diabetes complications may contribute to the development of sleep impairments 
[13-15]. Individuals suffering from sleep disorders often experience apnea, hypopnea, hypoxia, 
and frequent arousals during sleep. This type of disturbed breathing can lead to increased insulin, 
insulin resistance, and presence of the metabolic syndrome, and therefore, contribute to the 
development of diabetes [16]. Furthermore, cortisol and catecholamines, hormones regulated by 
sleep, can elevate blood glucose when sleep is disturbed [16]. Chronic sleep deprivation may 
therefore lead to an increase in hemoglobin A1c. On the other hand, diabetes symptoms and 
complications, such as nocturia, hypoglycemia, or pain due to neuropathy, may keep individuals 
with diabetes awake at night and disturb their sleep [16]. Until this vicious cycle is broken by 
prevention or treatment, it will continue to interfere with the lives of individuals suffering from 
diabetes and/or sleep disorders.  
The majority of studies that have linked sleep disorders with diabetes have focused on type 
2 diabetes mellitus [9-15]. Although a relationship between sleep disorders and type 1 diabetes 
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mellitus has been studied, most of the studies conducted to the present date are limited to youth 
[17-18, 20-21] and small samples [17-22]. Thus, the aim of our study was to describe the 
prevalence of OSA risk in a cohort of adult individuals with long standing type 1 diabetes. We 
further aimed to determine factors associated with OSA risk in this cohort and specifically, whether 
lifestyle factors (e.g. obesity), diabetes related factors (e.g. glycemic control), and diabetes 
complications status (e.g. coronary artery disease) differed among individuals at high OSA risk 
and those with normal sleep patterns. 
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2.0  DIABETES MELLITUS 
Diabetes mellitus is a group of chronic metabolic disorders marked by high blood glucose levels 
(i.e. hyperglycemia) that can cause serious health conditions such as heart disease, stroke, kidney 
failure, and blindness [1]. This complex disorder of carbohydrate, fat, and protein metabolism is 
typically a result of deficiency or lack of insulin secretion by the beta cells of the pancreas or a 
result of insulin resistance [23]. Individuals suffering from diabetes are often diagnosed after 
seeking medical attention due to clinical symptoms such as excessive thirst, hunger, and urination 
[23]. Two most commonly recognized forms of diabetes are type 2 and type 1 diabetes mellitus.  
2.1 TYPE 2 DIABETES MELLITUS 
Type 2 diabetes, formerly known as the non-insulin dependent diabetes mellitus, is the most 
common form of diabetes around the world. It is responsible for 90-95% of all diagnosed diabetes 
cases among adults [1]. This chronic condition is marked by the body’s ineffective use of insulin 
(i.e. a hormone responsible for controlling blood glucose) [1]. The onset of the disorder is typically 
gradual. Early in the disease process, the pancreas usually produces enough insulin, but the cells 
in the muscle, liver, and adipose tissue cannot utilize it effectively (i.e. insulin resistance) [1]. 
Eventually, insulin production significantly decreases or completely ceases. This form of diabetes 
used to be primarily associated with older age, but it is now seen among children and youth as 
well, as the rates of overweight and obesity, the disease’s major risk factors, have been increasing 
in those age groups [1].  Type 2 diabetes is highly related to lifestyle behaviors that lead to excess 
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body weight, such as physical inactivity, high-fat, and high-carbohydrate diet [1]. Importantly, a 
large multi-center clinical trial in the United States (Diabetes Prevention Program) demonstrated 
that the onset of type 2 diabetes can be prevented with lifestyle improvements or with use of oral 
antidiabetic medications (i.e. metformin) [24]. Other risk factors associated with this chronic 
metabolic disorder are familial diabetes history, history of gestational diabetes, and ethnicity (e.g. 
African Americans, American Indians, and Hispanics).  
2.2 TYPE 1 DIABETES MELLITUS 
Formerly recognized as the insulin-dependent diabetes mellitus, type 1 diabetes encompasses 
around five percent of all diagnosed diabetes cases [1]. This form of diabetes was previously 
known as juvenile-onset diabetes as its diagnosis most frequently occurs in children and youth [1]. 
However, type 1 diabetes can appear at any age. This autoimmune chronic condition develops 
when the immune cells attack and destroy insulin-producing beta cells in the pancreas, leading to 
the cessation of insulin secretion [23]. As a result, individuals suffering from type 1 diabetes need 
external insulin to survive. Although, type 1 diabetes has been linked to different genetic and 
environmental factors such as human leukocyte antigen genes and viral infections [23], the exact 
cause of the disease is still unknown. In addition, no known ways currently exist to prevent or cure 
type 1 diabetes mellitus.  
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3.0  OBSTRUCTIVE SLEEP APNEA 
OSA, the second most common sleep disorder in the US after insomnia [6], is characterized by 
loud snoring, witnessed breathing pauses, chocking or gasping during sleep, insomnia, and 
daytime sleepiness.  Individuals suffering from OSA exhibit complete or partial cessation of 
airflow as a result of upper airway collapse that lasts at least 10 seconds (i.e. apnea) [25]. Another 
major characteristic of OSA is hypopnea defined as a reduced airflow to the lungs by at least 30% 
that lasts a minimum of 10 seconds and is associated with a four percent oxygen desaturation, or 
a reduced airflow to the lungs by at least 50% that lasts a minimum of 10 seconds and is either 
associated with a three percent oxygen desaturation or an arousal from sleep [25].  
Polysomnography (i.e. sleep study) is the gold standard for diagnosing OSA. Severity of OSA is 
measured by the average number of apneas and/or hypopneas per hour of sleep and defined by the 
apnea-hypopnea index (AHI) [25]. Individuals with the AHI between five and 15 events per hour 
are thought to suffer from mild OSA [25]. Those with the AHI between 15 and 30 events per hour 
are categorized as having moderate OSA [25]. Finally, individuals with the AHI greater than 30 
events per hour suffer from severe OSA [25]. Common risk factors that have been associated with 
the development of OSA are obesity, central body fat distribution, large neck circumference, 40 to 
70 years of age, male gender, menopause, and ethnicity (e.g. African American) [25]. Furthermore, 
chronic health conditions such as hypertension, coronary heart disease, stroke, and type 2 diabetes 
have either been shown to frequently coexist with OSA or to be adverse consequences associated 
with it [25]. 
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3.1 OBSTRUCTIVE SLEEP APNEA AND TYPE 2 DIABETES MELLITUS 
As it has been previously stated, recent studies have found that sleep disorders may contribute to 
the development of type 2 diabetes [9-12], while diabetes complications may contribute to the 
development of sleep impairments [13-15]. Type 2 diabetes and OSA share obesity as a major risk 
factor, which might partially explain their inter-relationship and high concurrence. In addition, 
both conditions are also marked with insulin resistance [26]. The higher prevalence of OSA among 
individuals with type 2 diabetes [27] than in the general population warrants healthcare 
professionals to evaluate the risk of OSA among the diabetes population, but also to evaluate the 
risk for type 2 diabetes among individuals suffering from OSA.  
3.2 OBSTRUCTIVE SLEEP APNEA AND TYPE 1 DIABETES MELLITUS 
While the major risk factor for OSA, obesity, is highly prevalent among individuals with type 2 
diabetes, it is not uncommon to encounter high obesity rates among the type 1 diabetes population 
as well. For instance, in a well-established cohort of adult individuals with type 1 diabetes, the 
prevalence rates of overweight and obesity in the late 1980’s were 28.6% and 3.4%, respectively 
[28]. After 18 years of follow-up these figures increased to 42% and 22.7%, respectively, at a 
higher rate than in the general population [28]. As the type 1 diabetes phenotype is changing, 
assessing the risk for OSA in this population is becoming more relevant. Furthermore, other factors 
associated with type 1 diabetes such as poor glycemic control and respiratory events during sleep 
relating to nocturnal hypoglycemia [18] (as later discussed) are also important for consideration 
while evaluating the risk of OSA in this population.  
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However, research studies among adults with type 1 diabetes are rare. Importantly, existing 
data on the prevalence of sleep apnea among individuals with this diabetes type, the majority of 
which conducted among youth/adolescents, are limited by the small number of individuals (7 to 
50) evaluated [17-22].   
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4.0  METHODS 
The purpose of this research was therefore to evaluate the prevalence of, as well as factors 
associated with, obstructive sleep apnea risk in a large cohort of long duration type 1 diabetes. We 
sought to identify the extent of the problem (i.e. sleep apnea) in this cohort as well as potentially 
modifiable risk factors associated with its presence.  In addition, given prior publications 
suggesting gender differences in both the incidence of type 1 diabetes complications [29] as well 
as in risk factors associated with complication development [30-32], we further aimed to assess 
the potential role of gender in the presentation of sleep apnea risk.  
This thesis specifically focused on addressing the following gaps in knowledge: 
1) To determine the prevalence of sleep apnea risk among adults with long duration of type 
1 diabetes and evaluate the presence of gender differences in its prevalence. 
2) To identify risk factors associated with sleep apnea risk among adults with long duration 
of type 1 diabetes and evaluate the presence of differences in such factors by gender. 
4.1 STUDY POPULATION 
The study population comprised participants from the Pittsburgh Epidemiology of Diabetes 
Complications (EDC) study - an ongoing, 25-year prospective cohort of childhood-onset type 1 
diabetes [33-34]. The EDC study was based on individuals diagnosed (or seen within one year of 
diagnosis) with incident childhood-onset (before age 17) type 1 diabetes at Children’s Hospital of 
Pittsburgh between 1950 and 1980.  Investigators recruited individuals residing within 100 miles 
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or two hours’ drive from Pittsburgh, PA (n=658) and a first examination occurred between 1986 
and 1988. This cohort has previously been shown to be representative of the type 1 diabetes 
population in Allegheny County, PA [35].  At baseline, the mean age of participants was 28 years, 
and their mean duration of diabetes was 20 years. Study participants were subsequently re-
examined or surveyed every 2 years. The study protocol was approved by the University of 
Pittsburgh Institutional Review Board and all participants provided written informed consent prior 
to the initiation of any study procedure. Demographic, health care, diabetes self-care, and medical 
history information was obtained through self-administered questionnaires prior to each clinic 
visit.   
During the 25-year examination that took place at the EDC clinic visit at the University of 
Pittsburgh between 2011 and 2014, a validated tool (as later discussed), the Berlin Questionnaire 
(BQ) [36], was introduced by a trained research assistant to the EDC participants for the first time 
to assess their risk of OSA. In addition to completing the questionnaire, individuals were also 
asked to report a history of diagnosed sleep apnea. A total of 170 out of 195 individuals who 
completed the questionnaire as of March 23rd, 2014 were included in this cross-sectional analysis. 
4.2 THE BERLIN QUESTIONNAIRE 
The BQ is a screening instrument used for classifying individuals as being at high or low risk for 
OSA through identifying their snoring behavior, daytime sleepiness, and history of obesity or 
hypertension. The questionnaire is divided into three categories concerned with 1) snoring (its 
loudness, frequency of occurrence, and whether it bothers other people) and cessation of breathing 
during sleep, 2) tiredness and fatigue, and 3) body mass index (BMI) and history of hypertension, 
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for a total of 10 questions. Individuals scoring positively on two or all of the three categories are 
considered to be at high risk for OSA.  Those scoring positively on one or none of the categories 
are considered to be at low risk for OSA. The BQ questionnaire has been previously validated in 
a community survey and in a primary care setting against the sleep studies [36]. In primary care 
patients who were identified to be at high risk for OSA through a community survey (i.e. the BQ) 
and who then underwent sleep studies, the sensitivity and specificity were found to be 86% and 
77%, respectively, while a positive predictive value and a likelihood ratio were 89% and 3.79, 
respectively [36]. The BQ was also previously validated in preoperative patients against different 
AHI scores obtained through in-laboratory polysomnography [37]. Obtained sensitivity, 
specificity, positive predictive value, and likelihood ratio at the AHI > 5 were 68.9%, 56.4%, 
77.9%, and 1.58, respectively [37]. At the AHI >15, these figures changed to 78.6%, 50.5%, 
50.9%, and 1.59, respectively [37]. This validation study demonstrated similar results for the 
STOP questionnaire (i.e. a validated screening tool for OSA in surgical patients) and for the 
American Society of Anesthesiologists’ checklist for a routine screening of OSA in surgical 
patients.   
Our study participants were classified as being at high risk for OSA if they scored 
positively on the BQ and/or self-reported a positive history of OSA diagnosis.  
4.3 ANTHROPOMETRIC AND BLOOD PRESSURE MEASUREMENTS 
Weight and percent body fat were obtained from a balance beam scale with participants wearing 
light clothing and no shoes. Height was obtained using a stadiometer. BMI was calculated as 
weight in kilograms (kg) divided by height in meters squared (m2). Waist to hip ratio (WHR), a 
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measure of abdominal obesity, was calculated as the ratio of waist (measured at the midpoint 
between the highest point of the iliac crest and the lowest part of the costal margin in the 
midaxillary line) to hip (measured at the widest point of the glutei, usually at the level of the greater 
femoral trochanter) girth. Waist to height ratio (WHTR), a measure of central obesity, was 
calculated as the ratio of waist to height. Blood pressure was measured with a random zero 
sphygmomanometer after a five-minute rest according to the Hypertension Detection and Follow-
up Program Protocol [38]. The mean of the second and third readings was used. Hypertension 
(HTN) was defined as blood pressure ≥ 140/90 mm Hg or use of antihypertensive medications.  
4.4 LABORATORY MEASUREMENTS 
Fasting blood samples were taken. Blood glucose was obtained using the One Touch Ultra 
glucometer (LifeScan Inc., Milpitas, CA, USA). Hemoglobin A1c (HbA1c) was measured with 
the DCA 2000 Analyzer (Bayer, Tarrytown, NY, USA). Cholesterol and triglycerides were 
measured enzymatically by the Cholestech LDX System (Alere, Hayward, CA, USA), and high-
density lipoprotein cholesterol (HDLc) after dextran sulphate precipitation. Low-density 
lipoprotein cholesterol (LDLc) was calculated using a previously validated [39] Friedewald 
equation [40]. Non-HDLc was calculated by subtracting HDLc from total cholesterol. To evaluate 
participants’ insulin sensitivity, estimated glucose disposal rate (eGDR) was calculated using an 
equation derived from previous hyperinsulinemic euglycemic clamp studies (N=24) in which 
eGDR was highly related to glucose disposal during the clamp (r2=0.63) [41]. The equation was: 
eGDR = 24.395 – (12.971*WHR) – (3.388*(HTN; “yes”=1, “no”=0)) – (0.601*(HbA1c – 
1.13/0.81)). 
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4.5 DIABETES COMPLICATION ASSESSMENT 
All diabetes complications were obtained from the last available EDC examination cycle (2008-
2011). Coronary artery disease (CAD) presence was defined as by study-physician diagnosed 
angina, myocardial infarction confirmed by Q-waves on electrocardiogram (Minnesota codes 1.1 
or 1.2) or hospital records, angiographic stenosis >50%, coronary artery bypass surgery, 
angioplasty, ischemic electrocardiogram changes (Minnesota codes 1.3, 4.1-4.3, 5.1-5.3, 7.1), or 
CAD death. The definition of hard CAD (hCAD) excluded angina and ischemic electrocardiogram 
changes. The presence of end-stage renal disease (ESRD) was established by a self-report of renal 
transplantation or renal dialysis.  
4.6 OTHER COVARIATES 
The following variables were also obtained from the last available EDC examination cycle (2008-
2011). A history of severe hypoglycemia was defined as a hypoglycemic episode requiring 
external assistance (unconsciousness/seizure, required hospitalization, required help but did not 
recognize symptoms). History of stroke was determined through biennial surveys or physician 
interviews.  When possible, medical or autopsy records were obtained to verify the occurrence and 
type of stroke.  Confirmatory medical or autopsy records were obtained for 77% of the events.  
Stroke was defined as a neurological deficit of acute onset lasting ≥24 hours without other evident 
cause. Those participants who reported a history of smoking 100 or more cigarettes in their lifetime 
were considered past smokers.  
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4.7 STATISTICAL ANALYSIS 
Quantile-quantile plots and histograms were used to check the distributions of each of the 
continuous variables for normality. Descriptive statistics were then performed, displaying means 
(standard deviations) or medians (interquartile range) for normally distributed and non-normally 
distributed variables, respectively. Participant characteristics overall and according to the gender 
for the relevant variables (BMI, percent body fat, WHR, WHTR, eGDR, and HDLc) were 
described using means, medians, or proportions as appropriate. 
Univariate analyses were performed to describe the participants’ prevalence of OSA risk 
and to compare their characteristics according to OSA status. Two-sided Student’s t tests were 
used for normally distributed continuous variables, while two-sided nonparametric Wilcoxon’s 
rank-sum tests were used for non-normally distributed continuous variables. Two-sided χ2-tests or 
Fisher’s exact tests, where appropriate, were used to assess differences in the distribution of 
categorical variables by OSA risk status. A p-value < 0.05 was considered statistically significant. 
Analyses were also repeated stratifying by gender.  
Overall multivariable logistic regression was performed to assess independent correlates 
of the binary dependent variable of interest, OSA risk, and specifically, to assess whether lifestyle 
factors (i.e. obesity as measured by weight, BMI, percent body fat, waist and hip circumferences, 
WHR, and WHTR, systolic blood pressure (SBP), diastolic blood pressure (DBP), lipid profile, 
and smoking history), diabetes-related factors (i.e. fasting blood glucose, HbA1c, eGDR, HTN, 
and history of hypoglycemia that required assistance), and diabetes complications status (i.e. 
history of ESRD, CAD, hCAD, and stroke) differed among those individuals suffering from the 
outcome of interest and those with normal sleep patterns. Effect modification was assessed by 
testing plausible interaction terms (i.e. gender with BMI, HDLc, smoking history, and eGDR) at a 
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significance level of 0.10. Separate multivariable models were then built adjusting for gender and 
duration of diabetes and subsequently adding variables that were found to be statistically 
significant at an alpha level of 0.10 in the univariate analyses. Such variables were kept in the final 
regression model after ensuring that they were not collinear (r <0.6).  
Because the last category of the BQ is scored positively if an individual’s  BMI is greater 
than 30 kg/m2 and/or if they report having high blood pressure, multivariable analyses were 
repeated in the same model-building fashion as previously described, only excluding those 
individuals with a BMI > 30 kg/m2 and a positive HTN history. Due to the smaller sample size in 
these sub-analyses, a significance level of 0.10 was considered statistically significant.  
Finally, gender multivariable sub-analyses (via model-building) were also performed at a 
significance level of 0.10, first, by not excluding those individuals who satisfied the last criteria of 
the BQ, second, by excluding individuals with a BMI > 30 kg/m2, and third, by excluding the 
individuals with a BMI > 30 kg/m2 and a positive HTN history.  
All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, 
USA). 
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5.0  RESULTS 
One hundred ninety-five out of 376 (51.9%) eligible participants completed the BQ up to March 
23, 2014. A data freeze for this cross-sectional analysis occurred when 170 were entered (Figure 
1).  
 
                                                           376 Eligible 
 
 
  
                Participated                                                               Non-participation          
                256 (68.1%)                                                              120 (39.1%) 
 
Full participation (Clinic visit)           Questionnaires  
195 (51.9%)                                         61 (16.2%) 
 
 
 
Data entry completion as of data freeze 
170 (45.2%) 
 
Figure 1. Epidemiology of Diabetes Complications Study 25-year follow-up participation tree 
 
 
Table 1 shows the participants’ overall characteristics. The mean participants’ age was 51.4 
± 7.4 years and the median duration of diabetes was 42.3 (37.3, 46.6) years. About half (44.7%) 
were male. A self-reported history of diagnosed sleep apnea was present in 8.8% of the individuals. 
A little over a third of the participants (34.5%) reported having smoked at least 100 cigarettes in 
their lifetime. The participants were overweight with a median BMI of 26.8 (23.7, 30.9) kg/m2. 
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Women were slightly more overweight than men. While both median systolic and average diastolic 
blood pressure were within a healthy range (<120/80 mm Hg), the prevalence of HTN among the 
participants was found to be 33.1% driven mainly by the one third of the participants (32.9%) 
taking antihypertensive medications. The overall median HbA1c was 7.6% (6.9%, 8.4%), 
indicating good glycemic control over the three months before the examined clinical visit. The 
participants’ lipid profile was within normal limits. The overall insulin sensitivity, measured by 
the eGDR was 7.3 (5.7, 8.9) mg*kg-1*min-1, with women exhibiting higher insulin sensitivity than 
men (7.9 (6.2, 9.3) vs. 6.6 (4.6, 8.2) mg*kg-1*min-1, respectively). ESRD was reported among 
8.8% of the participants, while CAD and hCAD history were present in 27.1% and 21.8% of the 
individuals, respectively. A low number of participants (3.5%) reported a positive stroke history, 
while 87.4% reported a history of hypoglycemia that required assistance.   
Forty-four of the 170 participants (25.9% total prevalence; 25.0% males, 26.6% females) 
were at high OSA risk as per the BQ classification, in addition to a self-reported diagnosis of OSA.  
Of these 44 individuals, 15 had been previously diagnosed with OSA; five of these 15 individuals 
(33%) did not screen positively on the BQ. The OSA risk prevalence did not differ by gender (p-
value=0.813).  
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Table 1. Characteristics of the EDC participants  
Variable (unit) N Statistic* 
Age at exam (years) 170 51.4 ± 7.4  
Duration of diabetes (years) 
Males (%)     
Self-reported OSA (%)                                 
Smoking history (%) $ 
Height (cm) 
Weight (kg) 
170 
76/170 
15/170 
165 
170 
170 
42.3 (37.3, 46.6) 
44.7 
8.8 
34.5 
167.4 ± 9.5 
78.0 ± 15.9 
42.7 ± 6.6 
BMI (kg/m2)  
   Men 
   Women 
Body fat (%) 
    Men 
    Women 
Waist circumference (cm) 
Hip circumference (cm) 
170 
  76 
  94 
135 
  64 
  71 
167 
167 
26.8 (23.7, 30.9) 
26.5 (23.7, 30.5)  
27.4 (23.4, 31.9)  
28.5 (20.0, 38.6)  
20.0 (15.5, 26.0)  
36.9 (28.8, 44.8)  
90.8 (80.7, 101.9)  
104.4 (98.0, 111.6)  
27.8 ± 5.3 
27.3 ± 4.5 
28.4 ± 5.9 
29.7 ± 12.7 
21.3 ± 8.0 
37.3 ± 11.4 
92.0 ± 14.1 
105.5 ± 11.0 
Waist to hip ratio 
   Men 
   Women 
Waist to height ratio 
    Men 
    Women 
Hemoglobin A1c (%) 
Fasting blood glucose (mg/dL) 
eGDR (mg*kg-1*min-1) $ 
     Men 
     Women 
SBP (mmHg) 
DBP (mmHg) 
HTN (%) 
HTN medicine use ** (%)  
Pulse (beats/min) 
Total cholesterol (mg/dL) 
LDLc (mg/dL) 
HDLc (mg/dL) 
    Men 
    Women 
Non-HDLc (mg/dL) 
Total triglycerides (mg/dL)    
End-stage renal disease (%) $ 
CAD history (%) $    
Hard CAD history (%) $ 
Stroke history (%) $ 
Hypoglycemia (%) *** $ 
166 
  74 
  92 
166 
  74 
  92 
170 
165 
165 
  73 
  92 
168 
167 
56/169 
47/143 
169 
170 
147 
170 
  76 
  94  
168 
169 
15/170 
46/170 
37/170 
6/170 
125/143 
0.87 (0.81, 0.93) 
0.92 (0.86, 0.98)  
0.83 (0.77, 0.88)  
0.54 (0.48, 0.60)  
0.53 (0.49, 0.60)  
0.55 (0.47, 0.60)  
7.6 (6.9, 8.4) 
158.0 (115.0, 204.0)  
7.3 (5.7, 8.9) 
6.6 (4.6, 8.2)  
7.9 (6.2, 9.3)  
115.0 (106.5, 122.5)  
65.7 ± 9.0 
33.1 
32.9 
74.0 (66.0, 80.0) 
178.0 (153.0, 196.0)  
99.5 ± 30.4 
58.0 (47.0, 73.0) 
48.0 (41.5, 59.5)  
67.8 ± 18.4 
110.5 (95.0, 139.0)  
69.0 (49.0, 96.0) 
8.8 
27.1 
21.8 
3.5 
87.4 
0.87 ± 0.09 
0.92 ± 0.07 
0.83 ± 0.08 
0.55 ± 0.09 
0.55 ± 0.07 
0.55 ± 0.10 
7.7 ± 1.3 
168.2 ± 74.8 
7.1 ± 2.3 
6.3 ± 2.4 
7.8 ± 2.1 
117.1 ± 20.8 
 
 
 
73.0 ± 10.4 
176.2 ± 37.4 
 
60.4 ± 19.0 
51.3 ± 15.5 
 
117.0 ± 35.9 
89.2 ± 65.9 
*Values are either mean ± SD, median (25th %, 75th %) or sample size (%) 
** 27 missing values due to the data freeze for this analysis  
*** History of hypoglycemia that required assistance 
$ Variables obtained from the last available EDC examination cycle (2008-2011) 
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Univariately (Table 2), individuals at a high risk for OSA had a borderline longer duration 
of diabetes (p=0.089), were heavier (p=0.024), had a higher BMI (p=0.002), waist and hip 
circumferences (p=0.013, p=0.023, respectively), WHTR (p=0.009), SBP (p=0.033), and total 
triglycerides (p=0.005), as well as lower HDLc (p=0.045), and borderline lower eGDR (0.090); 
they were also more likely to report a positive history of smoking (p=0.091). The two groups did 
not significantly differ with respect to age, gender, HbA1c, fasting blood glucose, DBP, total and 
LDLc concentration, and history of HTN, ESRD, CAD, hCAD, stroke, and hypoglycemia that 
required assistance.   
The results from univariate analyses stratified by gender are displayed in Tables 3 and 4. 
Females at a high risk for OSA were on average heavier (p=0.020), had a higher BMI (p=0.003), 
waist and hip circumferences (p=0.023, p=0.040, respectively), WHTR (p=0.013), and total 
triglycerides (p=0.048), and a borderline higher WHR (p=0.054). They also reported a higher use 
of antihypertensive medications (p=0.037), and were more likely to have been diagnosed with 
CAD or hCAD (p=0.083 and p=0.065, respectively). In addition, high-risk OSA females had a 
lower HDLc concentration as well as eGDR (p=0.009 and p=0.037, respectively). The two groups 
of women did not significantly differ with respect to age, duration of diabetes, HbA1c, fasting 
blood glucose, systolic and diastolic blood pressure, total and LDLc levels, or in terms of a history 
of smoking, HTN, ESRD, stroke, and hypoglycemia that required assistance. 
Men with type 1 diabetes at high risk for OSA exhibited higher DBP (p=0.040), total 
cholesterol (p=0.034) and triglyceride concentrations (p=0.065), and were more likely to have 
reported a positive history of smoking (p=0.025) (Table 4). The two OSA groups of men did not 
significantly differ with respect to the rest of the demographic, clinical, or diabetes complications 
variables.  
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Table 2. Participants’ characteristics by OSA risk status* 
Variable (unit) N OSA low risk N OSA high risk p-value 
Age at exam (years) 
Males (%) 
126 
  57 
51.1 ± 7.3 
45.2 
44 
19 
52.1 ± 7.7 
43.2 
0.4499 
0.8133 
Duration of diabetes (years) 
Smoking history (%) $ 
Height (cm) 
Weight (kg) 
126 
38 
126 
126 
41.8 (36.4, 46.4), 42.2 ± 6.5 
30.9 
167.8 ± 9.5 
76.1 ± 14.3 
44 
19 
44 
44 
43.5 (39.3, 49.2), 44.1 ± 6.6 
45.2 
166.4 ± 9.6 
83.3 ± 18.9 
0.0887 
0.0914 
0.4099 
0.0241 
BMI (kg/m2)  
Body fat (%) 
Waist circumference (cm) 
Hip circumference (cm) 
126 
101  
124  
124  
26.4 (23.5, 30.0), 27.0 ± 30.1 
28.6 (20.1, 38.0), 29.3 ± 31.1 
90.6 (80.3, 96.7),  
90.0 ± 12.2 
103.3 (97.9, 109.7),  
104.2 ± 9.4 
44 
34 
42 
42 
29.6 (24.3, 36.1), 30.1 ± 6.5 
28.4 (18.8, 42.2), 31.1±15.5 
98.4 (81.4, 111.8),  
97.7 ± 17.6 
108.7 (98.2, 119.2) 
109.5 ± 14.3 
0.0024 
0.8235 
0.0130 
0.0232 
Waist to hip ratio 
Waist to height ratio 
Hemoglobin A1c (%) 
Fasting blood glucose (mg/dL) 
eGDR (mg*kg-1*min-1) $ 
SBP (mmHg) 
DBP (mmHg) 
HTN (%)   
HTN medicine use (%) 
Pulse (beats/min) 
Total cholesterol (mg/dL) 
LDLc (mg/dL) 
HDLc (mg/dL) 
Non-HDLc (mg/dL) 
Total triglycerides (mg/dL) 
End-stage renal disease (%) $ 
CAD history (%) $  
Hard CAD history (%) $ 
Stroke history (%) $ 
Hypoglycemia (%) ** $ 
124 
124 
126 
124 
123 
124 
123 
39 
33 
126 
126 
107 
126 
124 
126 
    9 
  31 
  24 
    4 
  93 
0.86 (0.81, 0.93), 0.86 ± 0.09 
0.52 (0.48, 0.58), 0.54 ± 0.07 
7.6 (6.9, 8.4), 7.7 ± 1.3 
160.5 (115.0, 203.5),  
167.3 ± 69.2 
7.7 (5.8, 9.1), 7.2 ± 2.3 
115.0 (105.0, 121.0), 
115.9 ± 21.4 
65.1 ± 8.8 
31.2 
30.3 
74.0 (66.0, 80.0), 73.2 ± 10.6 
175.0 (149.0, 196.0), 
175.0 ± 38.3 
98.6 ± 30.3 
60.0 (48.0, 75.0), 62.2 ± 19.0 
108.0 (92.5, 136.0), 
114.5 ± 34.9 
64.5 (44.0, 87.0),  
82.6 ± 56.8 
  7.1 
24.6 
19.0 
  3.2 
85.3 
42 
42 
44 
41 
42 
44 
44 
17 
14 
43 
44 
40 
44 
44 
43 
  6 
15 
13 
  2 
32 
0.89 (0.82, 0.94), 0.89 ±0.09 
0.60 (0.50, 0.66), 0.59 ±0.11 
7.5 (6.8, 8.4), 7.7 ± 1.3 
148.0 (101.0, 210.0), 
170.7 ± 90.5 
6.7 (5.3, 8.4), 6.6 ± 2.4 
117.5 (108.0, 129.0) 
120.5 ± 18.8 
67.4 ± 9.6 
38.6 
41.2 
72.0 (64.0, 80.0), 72.6± 10.1 
182.5 (160.5, 199.5), 
179.7 ± 34.9 
101.9 ± 31.0 
50.5 (41.0, 71.5), 55.5± 18.4 
122.0 (102.0, 145.0) 
124.3 ± 38.1 
78.0 (58.0, 126.0),  
108.5 ± 85.1 
13.6 
34.1 
29.5 
  4.5 
94.1 
0.1511 
0.0094 
0.9008 
0.6949 
0.0898 
0.0328 
0.1608 
0.3674 
0.2374 
0.8379 
0.1541 
0.5634 
0.0455 
0.1007 
0.0048 
0.2196 
0.2226 
0.1463 
0.6496 
0.2422 
* Values are either means ± SD, medians (25th %, 75th %) or sample size (%)
** History of hypoglycemia that required assistance 
$ Variables obtained from the last available EDC examination cycle (2008-2011) 
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Table 3. Participants’ characteristics by OSA risk status, women* 
Variable (unit) N OSA low risk N OSA high risk p-value 
Age at exam (years) 
Duration of diabetes (years) 
Smoking history (%) $ 
Height (cm) 
Weight (kg) 
69 
69 
23 
69 
69 
51.5 ± 7.2 
42.3 (36.6, 46.4), 42.4 ± 6.8 
34.3 
162.1 ± 6.4 
71.0 ± 12.6 
25 
25 
  9 
25 
25 
52.4 ± 6.9 
43.2 (39.3, 48.0), 43.9 ± 6.5 
37.5 
160.4 ± 7.3 
81.5 ± 20.1 
0.6082 
0.3167 
0.7801 
0.2852 
0.0204 
BMI (kg/m2)  
Body fat (%) 
Waist circumference (cm) 
 
Hip circumference (cm) 
69 
55   
68 
   
68   
26.5 (23.3, 30.0), 27.0 ± 4.9 
35.6 (28.8, 42.4), 36.5 ± 9.2 
86.1 (77.0, 92.5), 
86.6 ± 11.5 
105.8 ± 10.1 
25 
16 
24 
 
24 
32.5 (26.0, 36.9), 31.5 ± 7.1 
44.0 (27.6, 51.6), 40.0 ±16.9 
97.0 (79.8, 114.1), 
97.0 ± 19.4 
113.5 ± 16.5 
0.0030 
0.2739 
0.0228 
 
0.0405 
Waist to hip ratio 
Waist to height ratio 
Hemoglobin A1c (%) 
Fasting blood glucose (mg/dL) 
 
eGDR (mg*kg-1*min-1) $ 
SBP (mmHg) 
 
DBP (mmHg) 
HTN (%)    
HTN medicine use (%) 
Pulse (beats/min) 
Total cholesterol (mg/dL) 
LDLc (mg/dL) 
HDLc (mg/dL) 
Non-HDLc (mg/dL) 
 
Total triglycerides (mg/dL) 
 
End-stage renal disease (%) $  
CAD history (%) $  
Hard CAD history (%) $ 
Stroke history (%) $ 
Hypoglycemia (%) ** $ 
68 
68 
69 
68 
 
68 
69 
 
69 
19 
15 
69 
69 
61 
69 
67 
  
69 
 
  4 
13 
  9 
  3 
52 
0.82 (0.75, 0.87), 0.82 ±0.08 
0.53 (0.47, 0.58), 0.53 ±0.08 
7.7 ± 1.1 
169.5 (115.0, 211.5), 
169.5 ± 69.4 
8.6 (7.0, 9.5), 8.0 ± 2.0 
115.0 (105.0, 121.0), 
114.7 ± 17.1 
63.7 ± 8.8 
27.5 
25.0 
73.0 ± 8.6 
180.4 ± 33.9 
96.5 ± 28.2 
70.8 ± 16.8 
106.0 (91.0, 134.0), 
112.5 ± 32.7 
64.0 (48.0, 80.0), 
74.5 ± 45.1 
  5.8 
18.8 
13.0 
  4.3 
86.7 
24 
24 
25 
22 
 
24 
25 
 
25 
10 
10 
25 
25 
23 
25 
25 
 
24 
 
  3 
  9 
  8 
  1 
19 
0.86 (0.80, 0.90), 0.85 ±0.08 
0.62 (0.49, 0.68), 0.60 ±0.12 
7.7 ± 1.2 
147.5 (116.0, 210.0), 
170.0 ± 84.1  
6.8 (5.5, 8.5), 7.1 ± 2.2 
116.0 (108.0, 127.0), 
117.4 ± 14.8 
64.0 ± 9.5 
40.0 
50.0 
72.4 ± 8.4 
180.4 ± 35.5 
99.0 ± 33.3 
59.6 ± 20.4 
108.0 (99.0, 139.0), 
121.0 ± 39.4 
75.0 (56.5, 116.0), 
97.2 ± 58.5 
12.0 
36.0 
32.0 
  4.0 
95.0 
0.0542 
0.0126 
0.8012 
0.7283 
 
0.0363 
0.2711 
 
0.8893 
0.2477 
0.0367 
0.7536 
0.9926 
0.7275 
0.0085 
0.4476 
 
0.0481 
 
0.3778 
0.0825 
0.0647 
1.0000 
0.4375 
* Values are either means ± SD, medians (25th %, 75th %) or sample size (%) 
** History of hypoglycemia that required assistance 
$ Variables obtained from the last available EDC examination cycle (2008-2011) 
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Table 4. Participants’ characteristics by OSA risk status, men* 
Variable (unit) N OSA low risk N OSA high risk p-value 
Age at exam (years) 
Duration of diabetes (years) 
Smoking history (%) $ 
Height (cm) 
Weight (kg) 
57 
57 
15 
57 
57 
50.6 ± 7.3 
41.7 (36.1, 46.3), 41.8 ± 6.1 
26.8 
174.7 ± 8.0 
82.4 ± 13.7 
19 
19 
10 
19 
19 
51.7 ± 8.9 
43.5 (40.2, 49.2), 44.4 ± 7.0 
55.6 
174.3 ± 6.0 
85.8 ± 17.4 
0.5945 
0.1677 
0.0248 
0.8401 
0.3823 
BMI (kg/m2)  
Body fat (%) 
Waist circumference (cm) 
 
Hip circumference (cm) 
57 
46   
56 
   
56  
26.2 (23.8, 30.0), 27.0 ± 4.3 
19.3 (15.3, 23.8), 20.6 ± 7.8 
91.5 (85.6, 103.3),  
94.2 ± 11.8 
102.3 ± 8.2 
19 
18 
18 
 
18 
28.7 (23.4, 31.9), 28.2 ± 5.2 
21.5 (17.5, 28.5), 23.1 ± 8.5 
98.6 (87.2, 111.0), 
98.5 ± 91.0 
104.2 ± 8.4 
0.4285 
0.3135 
0.2870 
 
0.3941 
Waist to hip ratio 
Waist to height ratio 
Hemoglobin A1c (%) 
Fasting blood glucose (mg/dL) 
 
eGDR (mg*kg-1*min-1) $ 
SBP (mmHg) 
 
DBP (mmHg) 
HTN (%)   
HTN medicine use (%) 
Pulse (beats/min) 
Total cholesterol (mg/dL) 
 
LDLc (mg/dL) 
HDLc (mg/dL) 
Non-HDLc (mg/dL) 
 
Total triglycerides (mg/dL) 
 
End-stage renal disease (%) $ 
CAD history (%) $ 
Hard CAD history (%) $ 
Stroke history (%) $ 
Hypoglycemia (%) ** $ 
56 
56 
57 
56 
 
55 
55 
 
54 
20 
18 
57 
57 
 
46 
57 
57 
 
57 
 
  5 
18 
15 
  1 
41 
0.92 (0.86, 0.97), 0.92± 0.06 
0.52 (0.49, 0.59), 0.54± 0.07 
7.7 (6.8, 8.4), 7.8 ± 1.6 
158.0 (115.5, 191.5), 
164.7 ± 69.6 
6.6 (4.6, 8.2), 6.3 ± 2.4 
114.0 (106.0, 121.0), 
117.5 ± 25.8 
68.5 (59.0, 75.0), 67.0 ± 8.5 
35.7 
36.7 
73.3 ± 12.7 
170.0 (141.0, 182.0), 
168.5 ± 42.4  
101.4 ± 33.0 
48.0 (43.0, 57.0), 51.7 ±16.0 
115.0 (95.0, 139.0), 
116.8 ± 37.5  
65.0 (44.0, 108.0), 
92.3 ± 67.5 
  8.8 
31.6 
26.3 
  1.8 
83.7 
18 
18 
19 
19 
 
18 
19 
 
19 
  7 
  4 
18  
19 
 
17 
19 
19 
 
19 
 
  3 
  6 
  5 
  1 
13 
0.94 (0.86, 1.02), 0.95 ± 0.09 
0.56 (0.50, 0.63), 0.56 ± 0.08 
7.7 (6.8, 8.4), 7.8 ± 1.5 
171.0 (94.0, 218.0), 
171.6 ± 99.8 
6.4 (4.3, 8.4), 6.1 ± 2.6 
118.0 (113.0, 133.0), 
124.6 ± 22.9 
74.0 (66.0, 77.0), 71.9 ± 7.8 
36.8 
28.6 
73.0 ± 12.3 
183.0 (174.0, 198.0), 
178.8 ± 35.1 
105.8 ± 28.2 
47.0 (36.0, 62.0), 50.1 ± 14.1 
131.0 (107.0, 146.0), 
128.6 ± 36.8 
92.0 (69.0, 130.0), 
122.7 ± 110.2 
15.8 
31.6 
26.3 
  5.3 
92.9 
0.3351 
0.2986 
0.9426 
0.8550 
 
0.7734 
0.1188 
 
0.0396 
0.9295 
0.7532 
0.9183 
0.0342 
 
0.6335 
0.6965 
0.1231 
 
0.0655 
 
0.4045 
1.0000 
1.0000 
0.4400 
0.6697 
* Values are either means ± SD, medians (25th %, 75th %) or sample size (%) 
** History of hypoglycemia that required assistance 
$ Variables obtained from the last available EDC examination cycle (2008-2011) 
 
 
The presence of effect modification was assessed prior to constructing full multivariable 
models. No statistically significant interaction terms were observed between gender and any of the 
following variables: BMI, HDLc, smoking history, or eGDR (p=0.281, p=0.205, p=0.145 and 
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p=0.365, respectively). In the overall logistic regression analyses, all previously mentioned 
univariately significant variables at a p-value of 0.10 were subsequently individually added to a 
regression model along with duration of diabetes and gender. A total of nine models were thus 
built. Variables with a p-value < 0.10 comprised the final model. Weight (p=0.003), BMI 
(p=0.002), waist and hip circumferences (p=0.003 and p=0.009, respectively), WHTR (p=0.004), 
HDLc (p=0.014), and triglyceride levels (p=0.029) remained statistically significant after 
adjustment for diabetes duration and gender, smoking history remained borderline significant 
(p=0.097), and SBP lost its significance (p=0.385). Before arriving to the final regression model, 
each of the eight statistically significant variables were checked for multicollinearity. Because 
BMI was the most statistically significant variable in the model building process and was highly 
correlated with weight (r=0.824, p<0.0001), waist circumference (r=0.853, p<0.0001), hip 
circumference (r=0.885, p<0.0001), and WHTR (r=0.901, p<0.0001), it was the only variable out 
of the four that was chosen to stay in the final model. Therefore, in addition to BMI, the final 
model comprised duration of diabetes, gender, HDLc, triglycerides, and smoking history. Given 
that triglycerides lost statistical significance after controlling for the above mentioned variables 
(odds ratio (OR) 1.003 (95% confidence interval (CI) = 0.997, 1.009, p=0.375)), it was excluded 
from the final model. Therefore, BMI (directly), smoking history (inversely), and HDLc 
(inversely), emerged as correlates of OSA risk in the final logistic regression model (Table 5). 
Duration of diabetes remained a borderline positive correlate of OSA risk. While gender did not 
show statistical significance, it was “forced” to remain in the final model. BMI and smoking 
history were significantly positively associated with OSA status (OR 1.097 (95% CI=1.023, 1.177, 
p=0.010) and OR 2.266 (95% CI=1.046, 4.912, p=0.038), respectively), while HDLc showed a 
negative significant association (OR 0.974 (95% CI=0.950, 0.997, p=0.030). 
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Table 5. Final logistic regression model, overall analysis 
N=165; 42 (25.4%) events 
Variables selected 
in the final model OR 95% CI P-value 
Gender 
Diabetes duration 
1.560 
1.049 
0.659, 3.691 
0.991, 1.111 
0.3114 
0.0999 
BMI 1.097 1.023, 1.177 0.0095 
Smoking history $ 
HDLc 
2.266 
0.974 
1.046, 4.912 
0.950, 0.997 
0.0381 
0.0301 
$ Variable obtained from the last available EDC examination cycle (2008-2011) 
 
 
Sub-analyses were performed, excluding individuals with a BMI greater than 30 kg/m2 as 
well as those with a positive history of HTN, as those criteria were part of the BQ-determined OSA 
definition. However, adjusting for the duration of diabetes and gender, no further variables 
significantly contributed to the logistic regression model. 
Table 6 displays the overall final logistic regression model for female participants. This 
model was arrived to in the same manner as for the overall analyses. After controlling for duration 
of diabetes in the model-building process, along with all of the previously described univariately 
significant gender-specific variables, BMI (directly) and HDLc (inversely) emerged as OSA risk 
correlates in the final model. While, BMI was significantly positively associated with the outcome 
(OR 1.126 (95% CI=1.033, 1.226, p=0.007)), HDLc was significantly negatively associated with 
it (OR 0.968 (95% CI=0.940, 0.997, p=0.031)). 
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Table 6. Final logistic regression model, women 
N=94; 25 (26.6%) events 
Variables selected 
in the final model OR 95% CI P-value 
Diabetes duration 1.046 0.971, 1.127 0.2390 
BMI 1.126 1.033, 1.226 0.0068 
HDLc 0.968 0.940, 0.997 0.0315 
 
 
Further restricting multivariable analyses among women to those with a BMI < 30 kg/m2 
(Table 7), BMI lost its statistical significance, while HDLc and hCAD emerged as correlates of 
OSA risk in the final model (OR 0.966 (95% CI=0.927, 1.006, p=0.096) and OR 6.817 
(95%CI=1.214, 38.276, p=0.029), respectively). After further exclusion of women with a positive 
HTN history (Table 8), HDLc emerged as the only statistically significant variable while 
controlling for duration of diabetes (OR 0.948 (95% CI=0.899, 1.001, p=0.053)).  
 
Table 7. Final logistic regression model, women with a BMI ≤ 30 kg/m2 
N=62; 11 (17.7%) events 
Variables selected 
in the final model OR 95% CI P-value 
Diabetes duration 1.001 0.892, 1.124 0.9823 
HDLc 0.966 0.927, 1.006 0.0956 
Hard CAD $ 6.817 1.214, 38.276 0.0292 
$ Variable obtained from the last available EDC examination cycle (2008-2011) 
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Table 8. Final logistic regression model, women with a BMI ≤ 30 kg/m2 and no HTN 
N=46; 7 (15.2%) events 
Variables selected 
in the final model OR 95% CI P-value 
Diabetes duration 0.970 0.837, 1.124 0.6814 
HDLc 0.948 0.899, 1.001 0.0534 
 
 
Lastly, among men, controlling for duration of diabetes and subsequently adding each of 
the univariately significant gender-specific variables (DBP, total cholesterol, triglycerides, and 
smoking history) to the multivariable models, DBP (OR 1.115 (95% CI=1.024, 1.214, p=0.012)), 
and smoking history (OR 3.666 (95% CI=1.075, 12.505, p=0.038)) emerged as the positive OSA 
risk correlates in the final model (Table 9). 
 
Table 9. Final logistic regression model, men 
N=71; 18 (25.3%) events 
Variables selected 
in the final model OR 95% CI P-value 
Diabetes duration 1.100 0.991, 1.221 0.0748 
DBP 1.115 1.024, 1.214 0.0122 
Smoking history $ 3.666 1.075, 12.505 0.0380 
$ Variable obtained from the last available EDC examination cycle (2008-2011) 
 
 
 
Restricting the analyses to men with a BMI ≤ 30 kg/m2, DBP remained directly associated 
with the outcome (OR 1.124 (95% CI=1.019, 1.241, p=0.020), Table 10). However, in the final 
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model restricted to the male individuals with a BMI ≤ 30 kg/m2 and no HTN, DBP expectedly lost 
its statistical significance and no other variables significantly contributed to the model. 
 
Table 10. Final logistic regression model, men with a BMI ≤ 30 kg/m2 
N=51; 12 (23.5%) events 
Variables selected 
in the final model OR 95% CI P-value 
Diabetes duration 1.162 1.012, 1.334 0.0334 
DBP 1.124 1.019, 1.241 0.0200 
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6.0  DISCUSSION 
6.1 SUMMARY OF FINDINGS AND DISCUSSION OF LITERATURE 
In this cross-sectional analysis of 170 men and women in their early 50’s, with long-standing type 
1 diabetes, attending the 25-year examination of the Pittsburgh EDC study, we found that 
approximately one fourth were at a high risk for OSA regardless of gender. Three modifiable risk 
factors, BMI, smoking history, and HDLc concentration, were associated with a high risk for OSA 
after taking the participants’ duration of diabetes and gender into account. However, after 
excluding those individuals with a BMI greater than 30 kg/m2 and a positive history of HTN, the 
relationships between the previously mentioned modifiable risk factors and OSA status attenuated 
and none remained statistically significant. While the prevalence of high OSA risk did not 
significantly differ with respect to the participants’ gender, men and women exhibited different 
risk profiles for OSA. While BMI and HDLc were strongly associated with sleep apnea risk status 
in women and hCAD history was strongly correlated with OSA risk status in non-obese women, 
DBP and smoking history were isolated as correlates of high sleep apnea risk in men after 
accounting for the participants’ diabetes duration. In the more restrictive gender-specific sub-
analyses from which women and men with a BMI greater than 30 kg/m2 and a positive history of 
HTN were excluded, HDLc was still significantly inversely related to OSA risk status in women, 
while BMI became statistically insignificant. Similarly, the strong relationships between DBP and 
smoking history with the presence of high OSA risk became insignificant after the same 
restrictions were applied to men.  
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The OSA risk prevalence in this cohort of adults with long duration type 1 diabetes appears 
similar to the previously reported OSA prevalence in the general population [8]. Specifically, 
Heistand et al. (2006) examined the prevalence of OSA, as determined by the BQ scores, among 
1,506 nationally-representative adults (mean age 49 years) who completed the National Sleep 
Foundation’s Sleep in America 2005 Poll and found that 31% of men fell in the high-risk category 
compared to only 21% of women (p<0.001) [8]. However, in this study of individuals with type 1 
diabetes, we did not observe differences in OSA risk prevalence by gender. To our knowledge, to 
the present date there has only been one other study that has examined the prevalence of and risk 
factors associated with OSA risk (as determined by the BQ) in a sample of adults with long 
standing type 1 diabetes (N=99, 55.5% men, mean age 43.9 ± 1.3 years, mean duration of diabetes 
26.9 ± 1.3 years, mean BMI 24.5 ± 0.3 kg/m2, and mean HbA1c 7.8 ± 0.1 %) [42]. Compared to 
our study, van Dijk et al. (2011) found a slightly lower prevalence of high OSA risk (17.2%) [42]. 
However, our definition of OSA also included a diagnosis of self-reported sleep apnea. 
Nevertheless, even after excluding those individuals with an OSA diagnosis from the analysis, the 
total prevalence of high OSA risk in our study was still slightly higher (22.5 % total population, 
24.7% women, 19.7% men, p-value for a gender difference, 0.439) than in the previously 
mentioned study. Gender differences with respect to OSA risk status were not examined in the 
above mentioned study. It could be speculated, however, that the lower prevalence of OSA risk in 
the study by van Dijk et al. (2011) was likely a result of a younger population with a shorter 
duration of diabetes and a lower BMI.  
Fifteen out of 170 (8.8%) participants reported a previous diagnosis of sleep apnea, which 
is very comparable to self-reported rates (9%) of diagnosed sleep apnea in the U.S. [6]. Five of 
these participants did not score positively on the BQ, most likely due to active OSA treatment (via 
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continuous positive air pressure therapy (CPAP) during sleep). Though polysomnography would 
be required to objectively confirm the BQ-defined rates of OSA, these figures suggest that 29 out 
of 44 (65.9%) individuals who were determined to be at a high risk for OSA via the BQ remained 
undiagnosed, despite having a chronic condition such as type 1 diabetes, which requires frequent 
medical visits. In the general population, it has been reported that approximately 75-80% of 
individuals with OSA are undiagnosed [7]. Moreover, given that not all eligible study participants 
were able to attend the 25th-year clinical examination (during which the BQ was administered), 
the most frequent reason being related to complications associated with their type 1 diabetes, the 
true prevalence of OSA risk in our study population is likely higher than reported here. 
Previous studies that examined a relationship between sleep disorders and diabetes have 
mainly focused on adults with type 2 diabetes mellitus [9-15]. Although there have been studies 
that assessed such a relationship among individuals suffering from type 1 diabetes, most were 
limited to youth [17-18, 20-21] and small samples [17-22]. For instance, Villa et al. (2000) 
examined 25 children with type 1 diabetes (mean age 7.7 ± 2.0 years, mean duration of diabetes 
2.7 ± 2.6 years, mean BMI 18.7 ± 3.6 kg/m2, and mean HbA1c 7.8 ± 1.1 %) and 20 healthy controls 
of similar age and BMI after an overnight polysomnography and found that more cases than 
controls had sleep apneas (p= 0.006) and that they lasted longer (p= 0.07) [18]. In addition, patients 
with poorly controlled diabetes (HbA1c ≥ 8.0%) exhibited more apneas compared to patients with 
well controlled diabetes (HbA1c ≤ 7.9%) and to controls (p< 0.0001). Glycemic control and 
duration of diabetes correlated significantly with the respiratory events during sleep in the children 
with type 1 diabetes (r= 0.36, p=0.09, and r= 0.43, p= 0.04, respectively) [18]. Interestingly, in this 
study, we did not observe a significant relationship between glycemic control and OSA risk status 
in adults, as also previously reported among adult individuals with type 1 diabetes [42]. While this 
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finding may show that children and adults exhibit different risk factors associated with OSA, it is 
also possible that disturbed sleep patterns may still impair glucose metabolism in adults suffering 
from type 1 diabetes, but that this mechanism may not solely be reflected in the HbA1c values 
(although the participants from the abovementioned study [18], in which a significant relationship 
between sleep apneas and glycemic control was observed, had equally low HbA1c values as our 
participants). Other factors related to glycemic control/insulin sensitivity, such as obesity, lipid 
concentrations, and eGDR, may instead become more important in adulthood and play a greater 
role in the development of OSA. Specifically, our study found that BMI and HDLc concentration 
were independently associated with OSA risk status, while univariately, eGDR was significantly 
related to OSA risk in the overall EDC cohort and among women.  
A number of diabetes-related factors could be associated with disturbed sleep patterns, 
including modifiable lifestyle factors such as obesity, the aforementioned glycemic control, as well 
as diabetes-associated complications, such as CAD. Our study found that modifiable lifestyle 
factors including BMI, DBP, HDLc, and history of smoking, as well as unmodifiable disease 
states, e.g. hCAD history, were independently associated with OSA risk status. Previous studies 
have well established that obesity (measured by several markers including BMI, WHR, and neck 
circumference) is the strongest risk factor for OSA [25, 43-46] and that more than half of the 
prevalence of OSA can be attributed to excess body weight [43, 46]. Our study confirmed this 
finding as BMI was found to be the strongest independent correlate of OSA risk status. Moreover, 
when analyses were restricted to non-obese individuals (BMI less than 30 kg/m2) the associations 
with other OSA correlates attenuated. As obesity is highly associated with lipid concentrations 
[47], in particular, inversely with HDLc, it is not unexpected that we also found an association 
between OSA risk status and HDLc. However, previous studies that examined the relationship 
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between OSA and type 1 diabetes-related factors in adults did not focus on studying the association 
between OSA and lipid concentrations [42, 48].  
A potential pathophysiological association between OSA and obesity includes elevation of 
the “hunger hormone,” ghrelin, and resistance of the “satiety hormone,” leptin, as a result of sleep 
restriction, which contributes to obesity and, therefore, to insulin resistance [16]. During the 
insulin-resistant state, the counterregulatory hormones, glucagon, catecholamines, and cortisol, 
then increase blood glucose [16]. In addition, during the sleep-restricted state, growth hormone 
does not compete against catecholamines, which then further contributes to increasing blood 
glucose [16]. Sleep arousals also cause cortisol and catecholamines to elevate, and therefore, 
increase blood glucose [16]. In addition, hypoxia and interrupted sleep contribute to the release of 
cytokines, namely tumor necrosis factor alpha and interlukin-6, which are also linked to insulin 
resistance and diabetes [16]. Although, the present study was not designed to distinguish the 
mechanism of this cycle between OSA, obesity, and insulin resistance, the strong independent 
association between OSA risk status and obesity that we observed confirms the well-established 
link between the two conditions.  
Young et al. (2004) suggested that smoking also is a possible risk factor for OSA, though 
few studies were conducted to examine such a relationship [7]. They proposed that airway 
inflammation and smoking-associated disease may play a role in a relationship between smoking 
and OSA [7]. While our study found that past smoking history was independently associated with 
OSA risk, especially in men, the Wisconsin Sleep Cohort study [49] reported that current smokers 
were three times more likely to have OSA than former or never smokers and suggested that the 
effect of smoking on OSA is reversible after smoking cessation. Unfortunately, as of the writing 
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of this thesis, collected data on the EDC participants’ current smoking status were unavailable for 
the evaluation of its association with OSA status. 
HTN is another well-established risk factor associated with OSA [7]. While our study did 
not show that HTN history was independently associated with OSA risk status, DBP was found to 
be directly associated with the outcome in men. Schober et al. (2011) evaluated the prevalence of 
and risk factors associated with sleep disturbed patterns among adults with both type 1 and type 2 
diabetes (N=58 and 498, respectively) by assessing their airflow and pulse oximetry through a 
screening device named ApneaLink Oxi [48]. They also found a higher prevalence of 
hypertension, along with cardiovascular disease, heart failure, neuropathy, and nephropathy in a 
group of participants with moderate to severe OSA (AHI ≥ 15/hour). While an association between 
ESRD and OSA status was not seen in our study and we did not evaluate neuropathy and heart 
failure, we did find that non-obese women with a positive history of hard CAD had 6.8 times 
higher odds (p= 0.029) of being at high risk for OSA compared to non-obese women without a 
hard CAD event, after taking into account their diabetes duration and HDLc levels. Because both 
our study and the above-mentioned study were of cross-sectional nature, it is impossible to 
evaluate whether cardiovascular disease occurred before or after the individuals became at high 
OSA risk. However, while one previous prospective study (N=308, seven years of follow-up) 
found OSA to be an independent significant predictor of incident CAD (relative risk 4.6, 95% 
CI=1.83, 11.6, p= 0.001) [50], the same observational study also found that participants with 
prevalent OSA had an increased risk of developing CAD compared to those who snored but did 
not have OSA (16.2 % vs 5.4%, p= 0.003). Fortunately, another prospective study found a benefit 
of OSA treatment in reducing new cardiovascular events in CAD patients [51].  
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6.2 STUDY STRENGTHS AND LIMITATIONS 
To our knowledge, this is one of the first studies that evaluated the prevalence of and risk factors 
associated with OSA risk through a screening instrument in a well-phenotyped, relatively large 
adult population with long duration type 1 diabetes mellitus. In addition, to our knowledge our 
study was also the first to explore gender-specific risk factors associated with OSA risk status as 
determined by the Berlin Questionnaire. However, there are also certain limitations to the present 
study. Primarily, due to the cross-sectional nature of our analyses, it is impossible to establish 
temporality between OSA risk status and type 1 diabetes-related factors. Precaution should 
therefore be taken when interpreting the results of our study as they should be validated against 
future prospective data. Furthermore, given that our study population has survived type 1 diabetes 
for over 40 years, considerable survival bias is present in the current study. This type of bias may 
have resulted in an underestimation of the estimated prevalence of OSA risk, especially as the time 
during which the EDC population has been followed has been marked with increasing prevalence 
of the OSA’s major risk factor, obesity. As previously discussed, Conway et al. (2010) have 
confirmed the increasing prevalence of overweight and obesity in the type 1 diabetes cohort as 
well [28]. Lastly, because not all of the BQ data were available for timely analyses of this thesis, 
other potential correlates of OSA risk could have been overlooked or underestimated due to the 
limited size of the current sample.  
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6.3 FUTURE DIRECTIONS 
Upon availability of the rest of the BQ data, along with the diabetes complications data from the 
current EDC examination cycle, the present analyses will be repeated with the aim of re-evaluating 
the prevalence and correlates of OSA risk in a larger sample. In addition, an association between 
OSA risk status and diabetic autonomic neuropathy will be explored, given that this diabetes 
complication has been previously related to OSA [52]. Furthermore, prevalence and correlates of 
daytime sleepiness and other sleep disturbances, as determined by two additional screening tools, 
the Epworth Sleepiness Scale and the Pittsburgh Sleep Quality Index, which the EDC participants 
have completed for the first time during this 25-year follow-up, will also be explored.  
6.4 PUBLIC HEALTH SIGNIFICANCE 
The high OSA risk prevalence in this study population, as well as in the previously mentioned 
studies of adults with type 1 diabetes, is alarming. In addition to the previously recognized burden 
of undiagnosed OSA in the general population, our study showed that a potentially unrecognized 
burden of OSA among individuals with type 1 diabetes might also exist. Considering the ease of 
screening, availability of treatment, as well as the adverse consequences of OSA, this disorder 
constitutes a good public health target for early recognition and prevention among individuals who 
are already burdened with a serious chronic disease such as type 1 diabetes. Furthermore, two 
previous studies observed that effective CPAP treatment gradually decreased healthcare utilization 
costs among both men [53] and women [54] suffering from OSA syndrome (i.e. OSA with the 
symptoms of daytime sleepiness). Specifically, the number of annual physician visits for male 
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participants (N=342, age 48.2 ± 10.7 years) were high in the year before they were diagnosed with 
OSA syndrome (9.21 ± 0.44), but gradually decreased by the fifth year after diagnosis and CPAP 
therapy by 1.03 ± 0.49 (95%=CI -1.99, -0.07, p< 0.0001), which translated to a 13.92 ± 27.94 
(95% CI= -68.68, -40.83, p= 0.0009) Canadian dollar reduction in physician fees [53]. Similarly, 
the number of annual clinic visits for 231 CPAP compliant female participants (age 50.3 ± 0.7 
years) with OSA syndrome increased in the two years prior to diagnosis by 2.30 ± 0.57 and then 
decreased during the two years after diagnosis by 1.56 ± 0.55 visits (p<0.0001) [54]. This 
translated to a 20.96 ± 26.60 (p< 0.01) Canadian dollar reduction in physician fees [54]. However, 
effective CPAP therapy not only gradually decreased healthcare utilization costs [53-54], but it 
also had beneficial effects on reducing high blood pressure [55], new cardiovascular events [51], 
and even cardiovascular death among men [56] in other investigations. Thus, OSA screening may 
reduce social and financial burden, healthcare resources, as well as productivity lost due to further 
complication development often present in those with diabetes. 
While early OSA recognition and treatment in type 1 diabetes populations warrants great 
attention, reduction and prevention of risk factors associated with OSA might be of even greater 
public health importance. In fact, our study found that modifiable risk factors (i.e. BMI, HDLc, 
DBP, and smoking history) were independently associated with the OSA risk status. Improving 
such risk factors through embracing healthier lifestyle choices (e.g. exercising, eating a healthier, 
more balanced diet, and smoking cessation) may reduce OSA risk among individuals suffering 
from type 1 diabetes, not only by improving their wellbeing, but also by reducing the subsequent 
risk of developing further complications. However, future prospective studies are necessary to 
explore such a hypothesis, particularly due to the rapidly increasing rates of overweight and obesity 
in this population [28].  
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This study also found that hard CAD was associated with OSA risk in women. Although, 
once present hard CAD is not reversible, the aforementioned lifestyle choices can also be practiced 
to prevent incident CAD in female individuals [57-58], specifically through decreasing trans 
unsaturated fat intake [57] and increasing physical activity [58]. For instance, Hu et al. (1997) 
prospectively followed 80,082 women from the Nurses’ Health Study for 14 years (ages 34-59 
years, no known history of CAD, stroke, cancer, high cholesterol, or diabetes in 1980) and 
observed that each 2% energy intake increase from trans unsaturated fats was associated with a 
93% increase in the risk of developing heart disease (relative risk 1.93, 95% CI=1.43, 2.61, p < 
0.001) as compared to the equal energy intake from carbohydrates [57]. Manson et al. (1999) also 
prospectively followed the Nurses’ Health Study participants (N=72,488, ages 40-65 years, no 
known history of CAD or cancer in 1986) for eight years and observed a strong inverse relationship 
between physical activity and the risk for coronary events [58]. Namely, female participants in the 
top four quintiles for energy expenditure (increasing from the lowest quintile) had the following 
relative risks in comparison to the women in the lowest physical activity quintile group: 0.88, 0.81, 
0.74, 0.66, respectively (p for trend = 0.002), independent of their age, BMI, smoking status, 
alcohol consumption, menopausal status, familial history of hard CAD events, HTN, history of 
diabetes, history of high cholesterol, and other relevant covariates [58]. Furthermore, as previously 
discussed, among those persons with established CAD, effective OSA treatment may also reduce 
new cardiovascular events [51]. 
In conclusion, high OSA risk prevalence in our type 1 diabetes cohort, along with its 
modifiable correlates, deserves closer attention and further exploration.  
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APPENDIX: THE BERLIN QUESTIONNAIRE 
The following questions were completed by the Epidemiology of Diabetes Complications Study 
participants during their 25th-year clinical examination (2011-2014). In addition, a trained 
research assistant obtained a participant’s body mass index and blood pressure.  
1. Do you snore?  
_____ Yes 
_____   No 
_____   Don't know  
 
If you snore:  
2. Your snoring is…  
_____ Slightly louder than breathing  
_____ As loud as talking  
_____ Louder than talking  
_____ Very loud – can be heard in next         
room 
 
3. How often do you snore?  
_____ Nearly every day  
_____ 3-4 times a week  
_____ 1-2 times a week  
_____ 1-2 times a month 
_____ Never or nearly never  
 
4. Has your snoring ever bothered  
     other people? 
_____ Yes  
_____ No 
 
5. Has anyone noticed that you quit breathing      
in your sleep? 
_____ Nearly every day.  
_____ 3-4 times a week  
_____ 1-2 times a week  
_____ 1-2 times a month 
_____ Never or nearly never  
 
 
6. How often do you feel tired or fatigued after 
your sleep?  
_____ Nearly every day  
_____ 3-4 times a week  
_____ 1-2 times a week  
_____ 1-2 times a month 
_____ Never or almost never  
 
7. During your wake time, do you feel tired, 
fatigued or not wake up to par? 
_____ Nearly every day  
_____ 3-4 times a week  
_____ 1-2 times a week  
_____ 1-2 times a month 
_____ Never or almost never  
 
8. Have you ever nodded off or fallen asleep 
while driving a vehicle? 
_____ Yes 
_____ No 
 
9. If yes, how often does it occur? 
            _____ Nearly every day.  
            _____ 3-4 times a week  
            _____ 1-2 times a week  
            _____ 1-2 times a month  
            _____ Never or nearly never  
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